Knight Therapeutics Inc. (TSX: GUD) announced the full repayment of all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company drew $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, underscoring the company's financial discipline and operational strength.
The revolving credit facility, which continues to provide borrowing capacity of up to US$100 million, also includes an additional US$100 million accordion feature available subject to certain conditions. This structure supports Knight's ongoing growth strategy across its pan-American pharmaceutical business. The repayment reduces debt and interest expenses, strengthening the company's balance sheet and providing flexibility for future investments.
Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM. The company's shares trade on the TSX under the symbol GUD. For more information, visit www.knighttx.com.
The ability to repay the facility quickly highlights the success of the Paladin acquisition and the strong performance of Knight's portfolio. By using operational cash flow rather than additional financing, the company demonstrates its commitment to prudent financial management. This move is likely to be viewed positively by investors, as it reduces leverage and signals confidence in future earnings.
The Paladin acquisition expanded Knight's presence in the Latin American pharmaceutical market, adding a portfolio of branded and generic drugs. The strong cash flow from these operations, combined with Knight's Canadian business, enabled the rapid repayment. The company's growth strategy continues to focus on acquiring and commercializing pharmaceutical products in the region, leveraging its established infrastructure and expertise.
With the credit facility repaid, Knight retains significant borrowing capacity to pursue further acquisitions or invest in organic growth. The accordion feature allows the company to access additional funds if needed, providing flexibility to capitalize on opportunities. This financial strength positions Knight well in the competitive pharmaceutical landscape.
For more details on the press release, visit https://ibn.fm/8eluB. This announcement reflects Knight's commitment to delivering value to shareholders through strategic acquisitions and efficient capital management.
